WEBINAR: COVID-19 human challenge trials – what will be the regulatory considerations?


Join SGS experts and explore the potential of CHIM, COVID-19 regulatory considerations, working with regulators and how to accelerate your pipeline.


The current SARS-Cov-2 pandemic has brought the world to a standstill. Research groups and drug developers all over the world are scrambling to develop antivirals and vaccines to treat or prevent COVID-19. Longer term, better modeling will be required to test compounds in a controlled clinical setting once the pandemic has abated. Such a model could be a human challenge trial, commonly known as a controlled human infection model, or CHIM.

A coronavirus CHIM could be an ideal tool to support endeavors to develop effective COVID-19 interventions and provide a longer-term platform to support preparations against the emergence of new or novel coronaviruses.

This webinar will highlight the regulatory considerations to implement such a model and speed up the development pathway of much needed drugs and antiviral products.


  • Introduction to controlled human infection modeling (CHIM)
  • SARS-CoV-2: an introduction
  • Regulatory considerations surrounding COVID-19 modeling
  • Working with regulators on COVID-19 CHIM design and development
  • How a COVID-19 CHIM trial could accelerate your pipeline development
  • Q&A

When: April 28, 2020, 15:00 – 16:00
Where: online

More information and registration here.